Current Perspectives on Novel Drug Delivery Systems and Therapies for Management of Prostate Cancer: An Inclusive Review.
BACKGROUND
Prostate cancer (PC) is a prostate gland cells carcinoma, the foremost reason of cancer deaths in men in developed countries, representing most common malignancy in adult males. The key obstacle to achieve practicable therapeutic effect of active drugs and capable hopeful agents including proteins and peptides, and nucleic acid for prostate cancer is the scarcity of targeted drug delivery to cells of prostate cancer. As a result, need for novel systems, strategies or therapeutic approaches to enhance the assortment of active agents meant for prostate cancer becomes an important criterion. Currently cancer research focuses on improving treatment of prostate cancer using various novel drug delivery systems of chemotherapeutic agents. These novel drug delivery systems comprise nanoparticles and liposomes. Also, strategies or therapeutic approaches intended for the prostate cancer include radiation therapy for localized prostate cancer, hormonal therapy for suppressing tumor growth, and gene-and-immunologic therapy. These systems and approaches can deliver the drugs to their selected or targeted cancer cells for the drug release in cancer atmosphere of prostate thereby enhancing the effectiveness of tumor penetration.


OBJECTIVE
The objective was to collect and report the recent research findings to manage the PC. Present review encloses existing diverse novel drug delivery systems and approaches intended for the management of PC.


CONCLUSIONS
The reported miscellaneous novel drug delivery systems along with the diverse therapies are seem to be precise, secure and relatively effective; and in consequence could lead to a new track for obliteration of prostate cancer.
Department of Pharmaceutics, JSS College of Pharmacy, JSS University, Sri Shivarathreeshwara Nagar, Mysuru- 570015, Karnataka. India.
Rohit R
RR
Bhosale
Department of Pharmaceutics, JSS College of Pharmacy, JSS University, Mysuru- 570015, Karnataka. India.
H V
HV
Gangadharappa
Department of Pharmaceutics, King Khalid University, Abha- 62529. Saudi Arabia.
Umme
U
Hani
Department of Pharmaceutics, JSS College of Pharmacy, JSS University, Mysuru- 570015, Karnataka. India.
Riyaz
R
Ali M Osmani
Department of Pharmaceutics, JSS College of Pharmacy, JSS University, Mysuru- 570015, Karnataka. India.
Rudra
R
Vaghela
Department of Pharmaceutics, JSS College of Pharmacy, JSS University, Mysuru- 570015, Karnataka. India.
P K
PK
Kulkarni
Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS University, Mysuru- 570015, Karnataka. India.
Venkata Sairam
VS
Koganti
D000328:Adult; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use; D001918:Brachytherapy; D019468:Disease Management; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D008081:Liposomes / Q000737:chemistry; D008297:Male; D053758:Nanoparticles / Q000737:chemistry; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000628:therapy*
D000970:Antineoplastic Agents; D008081:Liposomes
Prostate cancer; brachytherapy; delivery systems; drug targets; gene therapy; orchiectomy